Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse glioma model

Radiation Research

Volumn 173, Issue 4, 2010, Pages 426-432

  Newcomb, Elizabeth W ^a   Lukyanov, Yevgeniy ^a   Kawashima, Noriko ^a   Alonso Basanta, Michelle ^a   Wang, Shu Chi ^a   Liu, Mengling ^a   Jure Kunkel, Maria ^b   Zagzag, David ^a   Demaria, Sandra ^a   Formenti, Silvia C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOMA; HUMAN; INTERFERON PRODUCTION; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GLIOMA; HUMANS; MICE; MICE, INBRED C57BL; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALIA; MURINAE; MUS;

EID: 77950221339     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1904.1     Document Type: Article

References (41)

1. R. Stupp, M. E. Hegi, M. R. Gilbert and A. Chakravarti, Chemoradiotherapy in malignant glioma; Standard of care and future directions. J. Clin. Oncol. 25, 4127-4136 (2007).
2. A. Narayana, P. Kelly, J. Golfinos, E. Parker, G. Johnson, E. Knopp, D. Zagzag, I. Fischer, S. Raza and M. L. Gruber, Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110, 173-180 (2009).
3. H. Okada, G. Kohanbash, X. Zhu, E. R. Kastenhuber, A. Hoji, R. Ueda and M. Fujita, Immunotherapeutic approaches for glioma. Crit. Rev. Immunol. 29, 1-42 (2009).
4. S. Rutowski, S. De Vleeschouwer, E. Kaempgen, J. E. A. Wolff, J. Kuhl, P. Demaerel, M. Warmuth-Metz, P. Flamen, F. Van Calenbergh and S. W. Van Gool, Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br. J. Cancer 91, 1656-1662 (2004).
5. H. H. Steiner, M. M. Bonsanto, P. Beckhove, M. Brysch, K. Geletneky, R. Ahmadi, R. Schuele-Freyer, P. Kremer, G. Ranaie and C. Herold-Mende, Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol. 22, 4272-4281 (2004).
6. C. J. Wheeler, K. L. Black, G. Liu, M. Mazer, X. X. Zhang, S. Pepkowitz, D. Goldfinger, H. Ng, D. Irvin and J. S. Yu, Vaccination elicts correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68, 5955-5964 (2008).
7. D. Zagzag, D. C. Miller, L. Chiriboga, H. Yee and E. W. Newcomb, Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo. Brain Pathol. 13, 34-37 (2003).
8. E. W. Newcomb, S. Demaria, Y. Lukyanov, Y. Shao, T. Schnee, N. Kawashima, L. Lan, J. K. Dewyngaert, D. Zagzag and S. C. Formenti, The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin. Cancer Res. 12, 4730-4737 (2006).
9. D. H. Lynch, The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol. Rev. 222, 277-286 (2008).
10. M. Croft, The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271-285 (2009).
11. R. G. Goodwin, W. S. Din, T. Davis-Smith, D. M. Anderson, S. D. Gimpel, T. A. Sato, C. R. Maliszewski, C. I. Brannan, N. G. Copeland and M. P. Beckmann, Molecular cloning of a ligand for the inducible T-cell gene 4-1BB: A member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 23, 2631-2641 (1993).
12. M. R. Alderson, C. A. Smith, T. W. Tough, T. Davis-Smith, R. J. Armitage, B. Falk, E. Roux, E. Baker, G. R. Sutherland and W. S. Din, Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24, 2219-2227 (1994).
13. z T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186, 47-55 (1997).
14. I. Gramaglia, D. Cooper, K. T. Miner, B. S. Kwon and M. Croft, Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur. J. Immunol. 30, 392-402 (2000).
15. K. E. Pollok, Y. J. Kim, Z. Zhou, J. Hurtado, K. K. Kim, R. T. Pickard and B. S. Kwon, Inducible T cell antigen 4-1BB. An analysis of expression and function. J. Immunol. 150, 771-781 (1993).
16. J. C. Hurtado, S. H. Kim, K. E. Pollock, Z. H. Lee and B. S. Kwon, Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J. Immunol. 155, 3360-3367 (1995).
17. I. Melero, J. V. Johnston, W. W. Shuford, R. S. Mittler and L. Chen, NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity eleicited by anti-4-1-BB monoclonal antibodies. Cell. Immunol. 190, 167-172 (1998).
18. C. Takahashi, R. S. Mittler and A. T. Vella, Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162, 5037-5040 (1999).
19. J. L. Cannons, P. Lau, B. Ghumann, M. A. DeBenedette, H. Yagita, K. Okumura and T. H. Watts, 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 cells with similar efficacy. J. Immunol. 167, 1313-1324 (2001).
20. I. Melero, W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellstrom, R. S. Mittler and L. Chen, Monoclonal antibodies against the 4-1BB T-cell activation molecule can eradicate established tumors. Nat. Med. 3, 682-685 (1997).
21. J. A. Kim, B. J. Averbook, K. Chambers, K. Rothchild, J. Kjaergaard, R. Papay and S. Shu, Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res. 61, 2031-2037 (2001).
22. R. E. Miller, J. Jones, T. Le, J. Whitmore, N. Boiani, B. Gliniak and D. H. Lynch, 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169, 1792-1800 (2002).
23. V. Y. Taraban, T. F. Rowley, L. O'Brien, H. T. Chan, L. E. Haswell, M. H. Green, A. L. Tutt, M. J. Glennie and A. Al-Shamkhani, Expression and costimulatory effects of the TNF receptor superfamily member CD134 (OX40) and CD137 (4-1BB), and their role in the generation of antitumor immune responses. Eur. J. Immunol. 32, 3617-3627 (2002).
24. R. A. Wilcox, D. B. Flies, G. Zhu, A. J. Johnson, K. Tamada, A. I. Chapoval, S. E. Strome, L. R. Pease and L. Chen, Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109, 651-659 (2002).
25. S. Ju, S. C. Lee, T. H. Kwon, S. K. Heo, S. M. Park, H. N. Paek, J. H. Suh, H. R. Cho, B. Kwon and B. S. Kim, Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol. Cell Biol. 83, 344-351 (2005).
26. S. Demaria and S. C. Formenti, Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int. J. Radiat. Biol. 83, 819-825 (2007).
27. S. Teitz-Tennenbaum, Q. Li, R. Okuyama, M. A. Davis, R. Sun, J. Whitfield, R. N. Knibbs, L. M. Stoolman and A. E. Chang, Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J. Immunother. 31, 345-358 (2008).
28. S. C. Formenti and S. Demaria, Local control by radiotherapy: is that all there is? Breast Cancer Res. 10, 215 (2008).
29. S. C. Formenti and S. Demaria, Systemic effects of local radiotherapy. Lancet Oncol. 10, 718-726 (2009).
30. A. M. Seligman and M. J. Shear, Studies in carcinogenesis. VIII. Experimental production of brain tumors in mice with methylcholanthrene. Am. J. Cancer 37, 364-395 (1939).
31. S. Demaria, N. Kawashima, A. M. Yang, M. L. Devitt, J. S. Babb, J. P. Allison and S. C. Formenti, Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 15, 727-734 (2005).
32. F. Ito, Q. Li, A. B. Shreiner, R. Okuyama, M. N. Jure-Kunkel, S. Teitz-Tennenbaum and A. E. Chang, Anti-Cd137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64, 8411-8419 (2004)
33. R. M. Prins, S. K. Odesa and L. M. Liau, Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 63, 8487-8491 (2003).
34. M. Obeid, T. Panaretakis, N. Joza, R. Tufi, A. Tesniere, P. van Endert, L. Zitvogel and G. Kroemer, Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14, 1848-1850 (2007).
35. L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G. Mignot, M. C. Mauri, E. Ullrich and G. Kroemer, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007).
36. A. A. Lugade, J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger and E. M. Lord, Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174, 7516-7523 (2005).
37. S. Matsumura, B. Wang, N. Kawashima, S. Braunstein, M. Badura, T. O. Cameron, J. S. Babb, R. J. Schneider, S. C. Formenti and S. Demaria, Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181, 3099-3107 (2008).
38. J. G. Egen, M. S. Kuhns and J. P. Allison, CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
39. K. S. Peggs, S. A. Quezada, A. J. Korman and J. P. Allison, Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18, 206-213 (2006).
40. L. M. Myers and A. T. Vella, Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol. 26, 440-446 (2005).
41. M. Sznol, F. S. Hodi, D. F. Margolin, D. F. McDermott, M. S. Ernstoff, J. M. Kirkwood, C. Wojtaszedk, D. Feltquate and T. Logan, Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J. Clin. Oncol. 26 (Suppl.), abstract 3007 (2008).